Xenetic Biosciences Inc [NASDAQ: XBIO] gained 141.49% or 6.07 points to close at $10.36 with a heavy trading volume of 47214307 shares.
It opened the trading session at $11.72, the shares rose to $13.93 and dropped to $9.34, the range by which the price of stock traded the whole day. The daily chart for XBIO points out that the company has recorded 320.28% gains over the past six months.
If we look at the average trading volume of 30.65K shares, XBIO reached to a volume of 47214307 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Xenetic Biosciences Inc [XBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XBIO shares is $40.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XBIO stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Xenetic Biosciences Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 08, 2020.
The Price to Book ratio for the last quarter was 3.59, with the Price to Cash per share for the same quarter was set at 3.10.
Trading performance analysis for XBIO stock
Xenetic Biosciences Inc [XBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 234.19. With this latest performance, XBIO shares gained by 234.03% in over the last four-week period, additionally plugging by 320.28% over the last 6 months – not to mention a rise of 159.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XBIO stock in for the last two-week period is set at 93.75, with the RSI for the last a single of trading hit 1.40, and the three-weeks RSI is set at 0.76 for Xenetic Biosciences Inc [XBIO]. The present Moving Average for the last 50 days of trading for this stock 3.24, while it was recorded at 4.89 for the last single week of trading, and 3.43 for the last 200 days.
Xenetic Biosciences Inc [XBIO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Xenetic Biosciences Inc [XBIO] shares currently have an operating margin of -104.69%. Xenetic Biosciences Inc’s Net Margin is presently recorded at -126.03%.
Xenetic Biosciences Inc (XBIO) Capital Structure & Debt Analysis
According to recent financial data for Xenetic Biosciences Inc. ( XBIO), the Return on Equity (ROE) stands at -51.83%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -42.86%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Xenetic Biosciences Inc’s Return on Invested Capital (ROIC) is -69.28%, showcasing its effectiveness in deploying capital for earnings.
Xenetic Biosciences Inc (XBIO) Efficiency & Liquidity Metrics
Based on Xenetic Biosciences Inc’s (XBIO) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Xenetic Biosciences Inc (XBIO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Xenetic Biosciences Inc. (XBIO) effectively leverages its workforce, generating an average of -$1540000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.93% and a Quick Ratio of 5.93%, indicating strong ability to cover short-term liabilities.
Xenetic Biosciences Inc [XBIO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Xenetic Biosciences Inc posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.14. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for XBIO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Xenetic Biosciences Inc go to 49.05%.
An analysis of Institutional ownership at Xenetic Biosciences Inc [XBIO]
There are presently around $4.60%, or 5.68%% of XBIO stock, in the hands of institutional investors.
